Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer

Gynecol Oncol Rep. 2017 Jun 27:21:78-80. doi: 10.1016/j.gore.2017.06.013. eCollection 2017 Aug.


•We report an ovarian cancer patient with a prolonged response to immunotherapy.•Comprehensive genomic profiling may detect patients who benefit from immunotherapy.•Mutational burden thresholds for ovarian cancer may be lower than other cancers.

Publication types

  • Case Reports